



**breathtec**  
BIOMEDICAL INC

**NEWS RELEASE**

**Breathtec Biomedical Announces Resignation of Chief Executive Officer**

**Vancouver, British Columbia, September 20, 2017 Breathtec Biomedical Inc.** (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) announces that effective immediately, Guy La Torre has resigned as Director and Chief Executive Officer (“CEO”) of the Company to pursue other ventures. The Company wishes Guy the best with his future endeavours. An interim CEO will be appointed in due course.

**ON BEHALF OF THE BOARD**

“Michael Sadhra”

Chief Financial Officer & Director

**CONTACT:**

Alfred Wong

Tel: 604 398 8840 ext 700

[info@breathtechbiomedical.com](mailto:info@breathtechbiomedical.com)

[investors@breathtechbiomedical.com](mailto:investors@breathtechbiomedical.com)

[www.breathtechbiomedical.com](http://www.breathtechbiomedical.com)

**ABOUT BREATHTEC BIOMEDICAL INC. (CSE: BTH) (OTCQB: BTHCF) (FRANKFURT: BTI)**

Breathtec Biomedical, Inc. (“Breathtec”) was formed to propel innovative research in the area of airborne analysis as a medical screening tool. Our efforts are aimed at leading the development of commercially viable methods for the early screening of certain pathogens. Our primary avenue of investigation is focused on innovation and advances in the field of specialized mass spectrometry. For more information: [www.breathtechbiomedical.com](http://www.breathtechbiomedical.com).

*CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.*

**Breathtec Biomedical Inc**

Suite 890, 789 West Pender Street, Vancouver BC V6C 1h2 Canada

General Inquiries: +1 (604) 646-5898

[www.breathtechbiomedical.com](http://www.breathtechbiomedical.com)

CSE: BTH | OTCQB: BTHCF | XFRA: BTI